Attached files

file filename
EX-32.1 - EX-32.1 - Viracta Therapeutics, Inc.snss-ex321_9.htm
EX-31.2 - EX-31.2 - Viracta Therapeutics, Inc.snss-ex312_8.htm
EX-31.1 - EX-31.1 - Viracta Therapeutics, Inc.snss-ex311_6.htm
EX-21.1 - EX-21.1 - Viracta Therapeutics, Inc.snss-ex211_7.htm
EX-4.1 - EX-4.1 - Viracta Therapeutics, Inc.snss-ex41_60.htm
10-K - 2020 10-K - Viracta Therapeutics, Inc.snss-10k_20201231.htm

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in the following Registration Statements:          

 

 

(1)

Registration Statement (Form S-8 No. 333-174732) pertaining to the 2011 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan of Sunesis Pharmaceuticals, Inc.,

 

(2)

Registration Statement (Form S-8 No. 333-180101) and Registration Statement (Form S-8 No. 333-187234) pertaining to the 2011 Equity Incentive Plan of Sunesis Pharmaceuticals, Inc.,

 

(3)

Registration Statement (Form S-8 No. 333-195781) and Registration Statement (Form S-8 No. 333-202696) pertaining to the 2011 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan of Sunesis Pharmaceuticals, Inc.,

 

(4)

Registration Statement (Form S-8 No. 333-210183) and Registration Statement (Form S-8 No 333-223632) pertaining to the 2011 Equity Incentive Plan of Sunesis Pharmaceuticals, Inc.,

 

(5)

Registration Statement (Form S-8 No. 333-217849) pertaining to the 2011 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan of Sunesis Pharmaceuticals, Inc.

 

(6)

Registration Statement (Form S-8 No. 333-231342) pertaining to the 2011 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan of Sunesis Pharmaceuticals, Inc.,

 

(7)

Registration Statement (Form S-8 No. 333-238141) pertaining to the 2011 Equity Incentive Plan and the 2011 Employee Stock Purchase Plan of Sunesis Pharmaceuticals, Inc., and

 

(8)

Registration Statement (Form S-4 No. 333-251567) of Sunesis Pharmaceuticals, Inc.

of our report dated February 24, 2021, with respect to the consolidated financial statements of Sunesis Pharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2020.

/s/ ERNST & YOUNG LLP

 

Salt Lake City, Utah

February 24, 2021